It’s still time to share your experiences in the iCMLf Hepatitis B Virus (HBV) and CML Screening and Management Survey. Your input is invaluable, and we look forward to learning from your clinical practice.

This survey is a key initiative to address the risk of HBV reactivation in CML patients receiving TKI therapy. Since there are currently no comprehensive guidelines and recommendations on HBV screening and monitoring for CML patients on TKIs, the data collected will help bridge this gap and inform future recommendations.

Submissions are welcome until February 27th, 2025.

HBV and CML Screening and Management Survey – Why your participation matters:

• Contribute to global knowledge: Share insights from your clinical experience managing CML patients with HBV.
• Support guideline development: Help shape the creation of practical recommendations for HBV monitoring and treatment during TKI therapy.
• Scientific publication: Your contributions will be part of a global survey that could culminate in a published paper, providing evidence-based recommendations for clinical practice.

Learn more about the HBV in CML Screening and Management Survey here

Take part here

Thank you for your continued support of this important research project. We will keep you updated on the progress and final publication of the findings.

iCMLf HBV Working Group:
Chair, Dragana Milojkovic (UK),
Katia Pagnano (Brazil),
Qian Jiang (China),
Delphine Réa (France),
Hemant Malhotra (India),
Fausto Castagnetti (Italy), 
Giuseppe Saglio (Italy),
Salam Al Kindi (Oman), 
Mohamed Yassin (Qatar), 
Charles Chuah (Singapore), 
Jorge Cortes (USA)